Alert detail
FDA Approval: ORSERDU (ELACESTRANT) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA217639Specialty: OncologyAdded: 6/30/2026Effective: 2023-01-27federal register
Full alert analysis requires a subscription
Subscribe to access the complete alert summary, AI-generated action recommendations, source document links, LCD revision comparisons, and related alerts.